NYSE:ABBVAbbVie Stock Price, Forecast & News

AbbVie's stock was trading at $84.85 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ABBV shares have increased by 16.7% and is now trading at $99.01. View which stocks have been most impacted by Coronavirus.

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 3 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for AbbVie.

AbbVie is scheduled to release its next quarterly earnings announcement on Friday, July 24th 2020. View our earnings forecast for AbbVie.

AbbVie Inc (NYSE:ABBV) issued its quarterly earnings results on Friday, May, 1st. The company reported $2.42 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.25 by $0.17. The company earned $8.62 billion during the quarter, compared to analyst estimates of $8.31 billion. AbbVie had a net margin of 24.77% and a negative return on equity of 169.80%. The business's revenue was up 10.1% on a year-over-year basis. During the same period last year, the firm earned $2.14 earnings per share. View AbbVie's earnings history.

AbbVie announced a quarterly dividend on Wednesday, June 17th. Shareholders of record on Wednesday, July 15th will be paid a dividend of $1.18 per share on Friday, August 14th. This represents a $4.72 dividend on an annualized basis and a dividend yield of 4.77%. The ex-dividend date of this dividend is Tuesday, July 14th. View AbbVie's dividend history.

AbbVie announced that its Board of Directors has authorized a share repurchase program on Thursday, December 13th 2018, which permits the company to buyback $5,000,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to repurchase up to 3.8% of its stock through open market purchases. Stock buyback programs are often an indication that the company's board believes its stock is undervalued.

AbbVie updated its FY 2020 After-Hours earnings guidance on Friday, May, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $50-50 billion.

17 analysts have issued 1 year price targets for AbbVie's stock. Their forecasts range from $90.00 to $125.00. On average, they anticipate AbbVie's share price to reach $106.80 in the next twelve months. This suggests a possible upside of 7.9% from the stock's current price. View analysts' price targets for AbbVie.

Media headlines about ABBV stock have been trending negative on Tuesday, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. AbbVie earned a news sentiment score of -2.1 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news about AbbVie.

Some companies that are related to AbbVie include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics (HZNP), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX), Corcept Therapeutics (CORT) and Zogenix (ZGNX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other AbbVie investors own include Intact Financial (IFC), Constellation Software (CSU), AutoCanada (ACQ), Alimentation Couche-Tard (ATD.B), Vermilion Energy (VET), Wheaton Precious Metals (WPM), Rogers Communications (RCI), Open Text (OTEX), Bristol-Myers Squibb (BMY) and Valeant Pharmaceuticals Intl (VRX).

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

AbbVie's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include State of Alaska Department of Revenue (0.02%), Park National Corp OH (0.01%), Thomasville National Bank (0.01%), Fulton Bank N. A. (0.01%), Red Spruce Capital LLC (0.00%) and Cox Capital Mgt LLC (0.00%). Company insiders that own AbbVie stock include Azita Saleki-Gerhardt, Brian L Durkin, Edward J Rapp, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Nicholas Donoghoe, Richard A Gonzalez, Roxanne S Austin, Timothy J Richmond and William J Chase. View institutional ownership trends for AbbVie.

ABBV stock was sold by a variety of institutional investors in the last quarter, including Municipal Employees Retirement System of Michigan, HNP Capital LLC, Park National Corp OH, Birch Capital Management LLC, Fulton Bank N. A., M&R Capital Management Inc., Truehand Inc, and Farmers Trust Co.. Company insiders that have sold AbbVie company stock in the last year include Jeffrey Ryan Stewart, and Timothy J Richmond. View insider buying and selling activity for AbbVie.

ABBV stock was acquired by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Nelson Van Denburg & Campbell Wealth Management Group LLC, Modus Advisors LLC, Ellevest Inc., Courier Capital LLC, OmniStar Financial Group Inc., Cox Capital Mgt LLC, and Burns J W & Co. Inc. NY. Company insiders that have bought AbbVie stock in the last two years include Brian L Durkin, Edward J Rapp, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Nicholas Donoghoe, Roxanne S Austin, and William J Chase. View insider buying and selling activity for AbbVie.

Shares of ABBV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ABBV stock can currently be purchased for approximately $99.01.

AbbVie has a market capitalization of $146.21 billion and generates $33.27 billion in revenue each year. The company earns $7.88 billion in net income (profit) each year or $8.94 on an earnings per share basis. AbbVie employs 30,000 workers across the globe.

The official website for AbbVie is www.abbvie.com.

AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The company can be reached via phone at 847-932-7900.